V. Lewis

发表

Surveillance of Creutzfeldt-Jakob disease in Australia: 2009 update.

C. Masters, A. McGlade, G. Klug, 2009, Communicable diseases intelligence quarterly report.

Cytosolic caspases mediate mislocalised SOD2 depletion in an in vitro model of chronic prion infection

C. Haigh, V. Lewis, S. Collins, 2013, Disease Models & Mechanisms.

Acute Neurotoxicity Models of Prion Disease.

P. Adlard, D. Finkelstein, V. Lewis, 2018, ACS chemical neuroscience.

Analysis of endogenous PrPC processing in neuronal and non-neuronal cell lines.

V. Lewis, S. Collins, 2008, Methods in molecular biology.

Markers of A1 astrocytes stratify to molecular sub-types in sporadic Creutzfeldt–Jakob disease brain

A. Hill, C. Mclean, V. Lewis, 2020, Brain communications.

Australian sporadic CJD analysis supports endogenous determinants of molecular-clinical profiles

C. Masters, A. Hill, G. Klug, 2005, Neurology.

Novel prion protein insert mutation associated with prolonged neurodegenerative illness

C. Masters, A. Hill, C. Mclean, 2003, Neurology.

The role of lipid rafts in prion protein biology.

N. Hooper, V. Lewis, 2011, Frontiers in bioscience.

Intra-cerebral haemorrhage but not neurodegenerative disease appears over-represented in deaths of Australian cadaveric pituitary hormone recipients

C. Masters, H. Wand, M. Law, 2020, Journal of Clinical Neuroscience.

Acute exposure to prion infection induces transient oxidative stress progressing to be cumulatively deleterious with chronic propagation in vitro.

C. Masters, C. Haigh, A. McGlade, 2011, Free radical biology & medicine.

Novel prion protein gene mutation presenting with subacute PSP-like syndrome

C. Masters, C. Masters, D. Rowe, 2007, Neurology.

Gerstmann-Sträussler-Scheinker disease associated with a novel PRNP mutation ( V 176 G ) harbours a distinctive clinical and molecular-pathological profile

C. Masters, Qiao-Xin Li, C. Mclean, 2014 .

Unusual clinical and molecular-pathological profile of gerstmann-Sträussler-Scheinker disease associated with a novel PRNP mutation (V176G).

C. Masters, Qiao-Xin Li, R. Pamphlett, 2013, JAMA neurology.

Correlative studies support lipid peroxidation is linked to PrPres propagation as an early primary pathogenic event in prion disease

C. Masters, A. Hill, R. Cappai, 2006, Brain Research Bulletin.

Transmissible spongiform encephalopathies in Australia.

C. Masters, A. Boyd, V. Lewis, 2001, Communicable diseases intelligence quarterly report.

Extended period of asymptomatic prion disease after low dose inoculation: Assessment of detection methods and implications for infection control

C. Masters, A. Hill, G. Klug, 2005, Neurobiology of Disease.

PrPSc Oligomerization Appears Dynamic, Quickly Engendering Inherent M1000 Acute Synaptotoxicity.

Blaine R. Roberts, P. Adlard, D. Finkelstein, 2020, Biophysical journal.

C. Masters, A. Hill, C. Haigh, 2009, Cell Research.

Creutzfeldt-Jakob disease: Australian surveillance update to March 2007.

C. Masters, G. Klug, A. Boyd, 2007, Communicable diseases intelligence quarterly report.

Creutzfeldt-Jakob disease surveillance in Australia January 1970 to December 2003.

C. Masters, G. Klug, A. Boyd, 2004, Communicable diseases intelligence quarterly report.

Surveillance of Creutzfeldt-Jakob disease in Australia: 2008.

C. Masters, A. McGlade, G. Klug, 2008, Communicable diseases intelligence quarterly report.

Analysis of Cellular Prion Protein Endoproteolytic Processing.

V. Lewis, 2017, Methods in molecular biology.

Prion protein “gamma-cleavage”: characterizing a novel endoproteolytic processing event

N. Hooper, P. Crouch, G. Klug, 2016, Cellular and Molecular Life Sciences.

Apparently sporadic CJD and covert health-care transmissions

C. Masters, A. Boyd, V. Lewis, 2002, The Lancet Neurology.

Comprehensive clinical, radiological, pathological and biochemical analysis required to differentiate VV1 sporadic Creutzfeldt-Jakob disease from suspected variant CJD

H. Butzkueven, F. Gaillard, V. Lewis, 2022, BMJ Neurology Open.

Early existence and biochemical evolution characterise acutely synaptotoxic PrPSc

Blaine R. Roberts, P. Adlard, D. Finkelstein, 2019, PLoS pathogens.

Increased Proportions of C1 Truncated Prion Protein Protect Against Cellular M1000 Prion Infection

C. Masters, A. Hill, C. Haigh, 2009, Journal of neuropathology and experimental neurology.

The cellular prion protein beyond prion diseases.

F. Fallarino, S. Mouillet-Richard, V. Lewis, 2020, Swiss medical weekly.

A Genome Wide Association Study Links Glutamate Receptor Pathway to Sporadic Creutzfeldt-Jakob Disease Risk

A. Hofman, A. Uitterlinden, F. Rivadeneira, 2015, PloS one.

The prion protein regulates beta-amyloid-mediated self-renewal of neural stem cells in vitro

Qiao-Xin Li, C. Haigh, T. Ryan, 2015, Stem Cell Research & Therapy.

Molecular Subtyping of PrPres in Human Sporadic CJD Brain Tissue.

G. Klug, V. Lewis, S. Collins, 2017, Methods in molecular biology.

Prion subcellular fractionation reveals infectivity spectrum, with a high titre-low PrPres level disparity

C. Masters, A. Hill, C. Haigh, 2012, Molecular Neurodegeneration.

Molecular typing of PrPres in human sporadic CJD brain tissue.

A. Hill, G. Klug, V. Lewis, 2008, Methods in molecular biology.

Prion acute synaptotoxicity is largely driven by protease-resistant PrPSc species

Blaine R. Roberts, P. Adlard, D. Finkelstein, 2018, PLoS pathogens.

In vivo prion models and the disconnection between transmissibility and neurotoxicity

P. Adlard, D. Finkelstein, V. Lewis, 2017, Ageing Research Reviews.

Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies.

A. Aguzzi, H. Budka, C. V. van Duijn, 2004, Brain : a journal of neurology.

Diagnostic performance of CSF biomarkers in a well-characterized Australian cohort of sporadic Creutzfeldt-Jakob disease

Qiao-Xin Li, J. Doecke, A. McGlade, 2023, Frontiers in Neurology.

The Three Glycotypes in the London Classification System of Sporadic Creutzfeldt-Jakob Disease Differ in Disease Duration

D. Velakoulis, Qiao-Xin Li, V. Lewis, 2021, Molecular Neurobiology.

Creutzfeldt–Jakob disease in Australia 1970–1999

J. Kaldor, C. Masters, M. Law, 2002, Neurology.

Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders in clinical settings

K. Blennow, C. Masters, S. Berkovic, 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.

Human transmissible spongiform encephalopathies in eleven countries: diagnostic pattern across time, 1993–2002

H. Budka, G. Jansen, C. V. van Duijn, 2006, BMC public health.

Erratum to: Creutzfeldt-Jakob disease surveillance in Australia: update to 31 December 2020.

C. Masters, A. McGlade, G. Klug, 2021, Communicable diseases intelligence.

Creutzfeldt-Jakob disease surveillance in Australia: update to 31 December 2021.

C. Masters, A. McGlade, G. Klug, 2022, Communicable diseases intelligence.

11C-PiB PET studies in typical sporadic Creutzfeldt–Jakob disease

C. Rowe, C. Masters, V. Villemagne, 2009, Journal of Neurology, Neurosurgery & Psychiatry.

For personal use. Only reproduce with permission The Lancet Publishing Group. Yet another spinocerebellar ataxia—will it ever end?

Andrew F. Hill, Victoria Lewis, A Boyd, 2002 .

Incidence of Human Astrovirus in Central Australia (1995 to 1998) and Comparison of Deduced Serotypes Detected from 1981 to 1998

V. Lewis, F. Morey, J. Erlich, 2002, Journal of Clinical Microbiology.

No evidence for prion protein gene locus multiplication in Creutzfeldt-Jakob disease

C. Duijn, C. Masters, B. Oostra, 2010, Neuroscience Letters.

Secreted cellular prion protein binds doxorubicin and correlates with anthracycline resistance in breast cancer.

Jamie R. Kutasovic, S. Lakhani, F. Al-Ejeh, 2019, JCI insight.

Cellular Prion Protein Expression Is Not Regulated by the Alzheimer's Amyloid Precursor Protein Intracellular Domain

N. Hooper, J. Manson, V. Lewis, 2012, PloS one.

Creutzfeldt-Jakob disease surveillance in Australia: update to 31 December 2020.

C. Masters, A. McGlade, C. Mclean, 2021, Communicable diseases intelligence.

Creutzfeldt-Jakob disease: Australian surveillance update to December 2005.

C. Masters, G. Klug, A. Boyd, 2006, Communicable diseases intelligence quarterly report.

Quinacrine does not prolong survival in a murine Creutzfeldt‐Jakob disease model

C. Masters, A. Hill, V. Lewis, 2002, Annals of neurology.

Creutzfeldt-Jakob disease surveillance in Australia: update to 31 December 2018.

C. Masters, C. Mclean, G. Klug, 2019, Communicable diseases intelligence.

Tailored behavioural tests reveal early and progressive cognitive deficits in M1000 prion disease

J. Kim, P. Adlard, D. Finkelstein, 2023, Neurobiology of Disease.

Creutzfeldt-Jakob disease surveillance in Australia: update to 31 December 2022.

A. McGlade, G. Klug, V. Lewis, 2023, Communicable diseases intelligence.

Communicable Diseases Intelligence 2022-Creutzfeldt-Jakob disease surveillance in Australia: update to 31 December 2021

C. Masters, A. McGlade, G. Klug, 2022 .

Creutzfeldt–Jakob disease surveillance in Australia: update to December 2017

C. Masters, V. Lewis, C. Stehmann, 2019, Communicable diseases intelligence.

Prion protein “gamma-cleavage”: characterizing a novel endoproteolytic processing event

N. Hooper, P. Crouch, G. Klug, 2015, Cellular and Molecular Life Sciences.

Increased Proportions of C1 Truncated Prion Protein Protect Against Cellular M1000 Prion Infection

C. Masters, A. Hill, C. Haigh, 2009, Journal of neuropathology and experimental neurology.

The role of lipid rafts in prion protein biology.

N. Hooper, V. Lewis, 2011, Frontiers in bioscience.

Acute Neurotoxicity Models of Prion Disease.

P. Adlard, V. Lewis, S. Biggi, 2018, ACS chemical neuroscience.

Alzheimer's disease biomarker utilization at first referral enhances differential diagnostic precision with simultaneous exclusion of Creutzfeldt‐Jakob disease

J. Doecke, A. McGlade, V. Lewis, 2024, Alzheimer's & dementia.